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The international prostate symptom score (IPSS) is widely used to 
assess the severity of lower urinary tract symptoms (LUTS) in men 
with bladder outlet obstruction (BOO) and to evaluate the response 
to medical or surgical therapy for benign prostatic obstruction 
(BPO).1 LUTS do not correlate well with prostate volume, maximum 
urinary flow rate (Qmax), post-void residual (PVR) urine volume or 
BOO as determined by urodynamic evaluation.2-6 Some studies have 
indicated that, although symptom scores may correlate with certain 
urodynamic parameters, these parameters do not correlate well with 
BOO.7
It has been suggested that invasive urodynamic evaluation 
(pressure-flow study) is indicated to prove that a patient’s LUTS 
are caused by BOO before invasive therapy is selected.8 However, 
for logistic reasons invasive urodynamic evaluation is not feasible 
in most men with LUTS. The IPSS is therefore widely used in 
combination with uroflowmetry to guide treatment decisions and 
to evaluate therapeutic response in men with LUTS probably caused 
by BOO.1
An important problem with the IPSS is that many patients find it 
difficult to comprehend. Studies showed that 30 - 70% of men could 
not complete the IPSS because they found the questions difficult to 
understand,9 and this problem was more common in men with a 
lower level of education.10
Van der Walt et al.11 recently developed a visual prostate symptom 
score (VPSS) using pictograms to assess four IPSS questions related 
to frequency, nocturia, weak stream and quality of life (QoL). The 
VPSS correlated significantly with the IPSS and could be completed 
without physician assistance by a greater proportion of men with 
limited education, indicating that it may be more useful than the IPSS 
in patients who are illiterate or have limited education.11
We aimed to evaluate the correlation between the VPSS and IPSS 
and non-invasive uroflowmetry parameters in men with LUTS. 
Patients and methods
The study was approved by the local institutional human research 
ethics committee. Men referred with LUTS were requested to 
complete the IPSS comprising the following questions: Q1 – 
incomplete emptying, Q2 – frequency, Q3 – intermittency, Q4 – 
urgency, Q5 – weak stream, Q6 – straining, Q7 – nocturia, Q8 – QoL 
due to urinary symptoms (maximum score 41). They were also 
requested to complete the VPSS (Fig. 1) comprising pictograms to 
evaluate the following questions: Q1 – frequency, Q2 – nocturia, Q3 
– force of the urinary stream, Q4 – QoL (maximum score 23). Study 
subjects who were unable to complete the questionnaires on their 
own were assisted by a doctor. 
A full medical history was obtained and physical examination, 
digital rectal examination (DRE) and dipstick urine analysis were 
performed. The Qmax, average urinary flow rate (Qave) and voided 
volume (VV) were measured using a Urodyn 1000 Plus uroflowmeter, 
after which the PVR was measured using a Toshiba JustVision 200 
ultrasound machine with a 2.3 MHz probe. A single urinary flow 
measurement was obtained in each subject. Serum creatinine and 
prostate-specific antigen (PSA) were also assayed. 
Statistical analysis was performed using MS Excel and GraphPad 
Instat software, with the Mann-Whitney test for comparison of 
means and Spearman’s test for correlation analysis. A two-tailed 
p-value <0.05 was accepted as statistically significant. 
Results 
During the period August 2009 - August 2010, a total of 96 men 
were enrolled (mean age 64 years, range 33 - 85). Uroflowmetry was 
performed in 93 men, with VV >150 ml in 66 (71%) cases and VV 
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Objective. A visual prostate symptom score (VPSS) compared with 
the international prostate symptom score (IPSS) for evaluation of 
lower urinary tract symptoms (LUTS) can be completed without 
physician assistance by a significantly larger proportion of men 
with limited education. We aimed to evaluate the correlation of the 
VPSS and IPSS with uroflowmetry parameters. 
Methods. Men with LUTS were requested to complete the IPSS 
and VPSS, consisting of pictograms to evaluate urinary frequency, 
nocturia, force of the stream and quality of life. The maximum 
(Qmax) and average urinary flow rate (Qave), voided volume 
(VV) and post-void residual (PVR) urine volumes were measured. 
Statistical analysis was performed using the Mann-Whitney and 
Spearman’s tests. 
Results. The study included 93 men (mean age 64 years, range 33 - 
85), with VV >150 ml in 66 (71%) and <150 ml in 27 (29%) subjects. 
In the group with VV >150 ml there were significant negative 
correlations between the IPSS and Qmax (r=-0.30, p=0.016), the 
IPSS and Qave (r=-0.29, p=0.018), the VPSS and Qmax (r=-0.38, 
p<0.002) and the VPSS and Qave (r=-0.37, p<0.003). The VPSS 
question on the subject’s assessment of his urinary stream showed 
a significant negative correlation with the Qmax (r=-0.37, p=0.002) 
and Qave (r=-0.31, p=0.011), but the IPSS question on the subject’s 
urinary stream did not correlate significantly with the Qmax or 
Qave. 
Conclusions. The VPSS is equivalent to the IPSS in terms of 
correlation with Qmax and Qave and can therefore be used instead 
of the IPSS to evaluate LUTS in men with limited education. 
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<150 ml in 27 (29%). The mean total IPSS was 20.9 (range 1 - 41) and 
the mean total VPSS was 13.7 (range 4 - 23). On DRE the prostate was 
clinically benign in 72 (77%) of the men and malignant in 21 (23%). 
The mean serum creatinine was 107.5 (range 65 - 232) µmol/l and the 
mean serum PSA was 30.7 (range 0.2 - 1601) ng/ml. 
There were no significant differences with regard to age, mean 
IPSS and mean VPSS in the groups with VV >150 ml or <150 
ml (Table I). The correlation between total IPSS and VPSS was 
statistically significant in both groups, but the correlations between 
Qmax and Qave versus total IPSS and VPSS, respectively, were only 
significant in the group with VV >150 ml (Table II). The correlations 
between Qmax and Qave and the subject’s assessment of his urinary 
stream were statistically significant for the VPSS (Q3) but not the 
IPSS (Q5) in the group with VV >150 ml but not in the group with 
VV <150 ml (Table II).  
There were statistically significant correlations between age and 
Qmax (r=-0.22, p=0.039), age and VV (r=-0.32, p=0.001) and age and 
serum PSA (r=0.21, p=0.042), but not between age and total IPSS, 
total VPSS, Qave, PVR or serum creatinine.  
There were significant correlations between VV and Qmax 
(r=0.611, p<0.000) as well as Qave (r=0.543, p=0.001), and between 
PVR and Qmax (r=-0.225, p=0.03) as well as Qave (r=-0.284, 
p=0.006). 
In the study group as a whole, Qmax correlated significantly with 
total IPSS as well as VPSS (Fig. 2). The correlations between Qave and 
total IPSS as well as VPSS were also significant in the study group as 
a whole (Fig. 3).  
Discussion
The concept of the VPSS was based on the observation by an author 
(AEG) that illiterate or poorly educated men found it impossible 
to complete the IPSS, even with physician assistance. In contrast, 
patients easily comprehended a simple diagram showing a urinating 
man, in which the patient can indicate the force of the urinary stream 
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Table I. Comparison of age, symptom scores and urinary flow parameters in subjects with VV >150 ml v. <150 ml 
VV ≥150 ml VV <150 ml p-value
No. of patients (%) 66 (71%) 27 (29%)
Mean age (yrs) (range) 63.1 (33 - 85) 65.8 (48 - 81) 0.298
Mean IPSS (maximum score 41) 
(range)
20.2 (4 - 33) 22.3 (1 - 41) 0.324
Mean VPSS (maximum score 23) 
(range)
13.3 (4 - 21) 14.7 (7 - 23) 0.215
Qmax (ml/s) (range) 14.8 (3.4 - 46.2) 8.1 (1.5 - 18.6) <0.001
Qave (ml/s) (range) 7.8 (2.3 - 31.2) 4.1 (0.9 - 9.3) <0.001
VV (ml) (range) 279.6 (151 - 663) 98.1 (20 - 148) <0.001
PVR (ml) (range) 116 (0 - 477) 149.7 (0 - 600) 0.337
VV = voided volume; IPSS = international prostate symptom score; VPSS = visual prostate symptom score; Qmax = maximum urinary flow rate; Qave = average urinary flow rate; PVR = post-
void residual urine volume.
The p-values in bold are statistically significant.
Table II. Comparison of correlations between symptom scores and urinary flow parameters in subjects with VV ≥150 ml v. <150 ml 
VV ≥150 ml VV <150 ml
Correlation coefficient (r) p-value Correlation coefficient (r) p-value
IPSS total v. VPSS total 0.73 <0.001 0.92 <0.001
IPSS total v. Qmax -0.30 0.016 -0.07 0.743
VPSS total v. Qmax -0.38 0.002 -0.01 0.980
IPSS total v. Qave -0.29 0.018 -0.16 0.410
VPSS total v. Qave -0.37 0.003 -0.10 0.619
IPSS QoL v. Qmax -0.16 0.211 +0.14 0.477
VPSS QoL v. Qmax -0.12 0.344 +0.09 0.660
IPSS QoL v. Qave -0.16 0.214 -0.11 0.590
VPSS QoL v. Qave -0.15 0.225 -0.06 0.767
IPSS Q5 v. Qmax -0.15 0.219 +0.01 0.948
VPSS Q3 v. Qmax -0.37 0.002 -0.30 0.132
IPSS Q5 v. Qave -0.11 0.370 -0.02 0.922
VPSS Q3 v. Qave -0.31 0.011 -0.39 0.043
VV = voided volume; IPSS = international prostate symptom score; VPSS = visual prostate symptom score; Qmax = maximum urinary flow rate; Qave = average urinary flow rate; QoL = quality 
of life; Q3 = question 3; Q5 question 5.
The p-values in bold are statistically significant.  
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corresponding to his own (Q3 in the VPSS, Fig. 1). However, the 
validity or reliability of this pictogram was not formally evaluated, 
and the perception of its usefulness was based on clinical observation 
only. The VPSS pictograms evaluating daytime urinary frequency, 
nocturia and QoL and the prospective evaluation protocol were 
developed by the first two authors and a medical illustrator. 
Whereas community-based studies show a positive correlation 
between patient age and symptom scores evaluating LUTS, in an 
outpatient setting there may be a negative correlation, because older 
patients may visit the outpatient department with lower scores than 
younger patients.5,12 In our study there was no significant correlation 
between age and total IPSS or VPSS, although there were relatively 
weak but statistically significant negative correlations with Qmax and 
VV, and a positive correlation with serum PSA. 
The International Consensus Committee on BPH recommended 
that uroflowmetry data with VV <150 ml should be regarded as 
unreliable. The proportion of men unable to produce a VV >150 
ml during uroflowmetry has been reported as varying from 20% 
to 5%.5 In this study the VV was <150 ml in 29% of cases, possibly 
because it was not a population-based study but a selected group of 
men with relatively severe LUTS. However, for logistic reasons it was 
not possible to repeat the uroflowmetry studies, and the analysis is 
based on a single study for each subject. Interestingly, the correlation 
of IPSS versus VPSS was somewhat stronger in the group with VV 
<150 ml (0.92) than in the group with VV >150 ml (0.73), but the 
correlation of IPSS and VPSS with Qmax and Qave was statistically 
significant only in the group with VV >150 ml (Table II).  
Previous studies have evaluated the correlation between symptom 
scores and uroflowmetry parameters. An analysis of 466 men 
40 - 79 years old reported the following Spearman’s rank correlation 
coefficients: American Urological Association symptom index (AUA-
SI) v. prostate volume 0.19, prostate volume v. Qmax 0.21, and AUA-
SI v. Qmax -0.35 (p<0.001).2 Bosch et al.12 reported a weak correlation 
of the IPSS with total prostate volume, Qmax and PVR. A study 
of 227 men evaluated with the IPSS and pressure-flow studies to 
determine the presence of BOO reported that Pearson’s test showed a 
significant positive correlation between symptoms and the presence 
of BOO.7
A study of 196 men reported the following Pearson’s correlation 
coefficients: IPSS v. QoL 0.65 (p<0.001), IPSS v. Qmax -0.12 (not 
significant), QoL v. Qmax -0.19 (p=0.008), Qmax v. PVR -0.21 
(p=0.003), and prostate volume v. Qmax -0.19 (p=0.008).3 They 
reported the following correlation coefficients: IPSS v. QoL score 
0.45 (p<0.001), QoL score v. Qmax -0.13 (p=0.005), and QoL v. PVR 
0.10 (p=0.03), but correlations for IPSS v. Qmax, PVR and prostate 
volume, and QoL v. prostate volume were not significant.3
In a study of 460 men 41 - 88 years old, Wadie et al.4 reported the 
following Spearman’s correlation coefficients: total IPSS v. Qmax 
0.1 (p=0.04), total IPSS v. Qave 0.16 (p<0.01), obstructive scores v. 
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Fig. 2. Correlation between Qmax and IPSS and VPSS, respectively, 
including the QoL question (Qmax = maximum urinary flow rate, IPSS 
= international prostate symptom score, VPSS = visual prostate symptom 
score, QoL = quality of life).   
Fig. 3. Correlation between Qave and IPSS and VPSS, respectively, including 
the QoL question (Qave = average urinary flow rate, IPSS = international 
prostate symptom score, VPSS = visual prostate symptom score, QoL = 
quality of life).   
Fig. 1. Visual prostate symptom score (VPSS) (© Stellenbosch University).
240 April 2012, Vol. 102, No. 4  SAMJ
Qmax (0.16, p<0.01) and Qave (0.2, p<0.01), and irritative scores v. 
Qmax and Qave not significant.4 They concluded that non-invasive 
urodynamics (uroflowmetry) only had a fair to moderate correlation 
with pressure-flow measurement.4 Seki et al.6 studied 557 men with 
symptomatic improvement (25% or more reduction of total IPSS) at 
3 months after transurethral resection of the prostate, and found that 
their LUTS were primarily due to BOO. They reported statistically 
significant correlations between total IPSS and Qmax (-0.20), QoL 
score and Qmax (-0.14), total IPSS and PVR (0.13), and QoL score 
and PVR (0.11).6
Our study showed statistically significant correlations of the IPSS 
v. Qmax (r=-0.28) and Qave (r=-0.29), and of the VPSS v. Qmax 
(r=-0.42) and Qave (r=-0.41). The correlation coefficients were of 
similar magnitude to other studies and were slightly higher for the 
VPSS than the IPSS. The relatively weak correlations could be partly 
due to using only single-void flow rate measurements in this study.13 
However, the magnitude of these modest correlations is similar to 
those in other diseases where strong relationships exist. For example, 
in patients with coronary artery disease the correlation between 
plasma cholesterol and coronary artery occlusion has been reported 
as 0.15, and in patients with asthma, QoL and asthma symptom 
scores showed correlations with 1-second forced expiratory volumes 
of -0.25 - -0.28.2
It is interesting that in this study there was a relatively strong 
correlation between total IPSS and VPSS scores in the group with VV 
>150 ml (0.73) and in the group with VV <150 ml (0.92, p<0.001), 
even though the correlations between total IPSS and VPSS on the one 
hand and Qmax and Qave on the other hand were not significant in 
the group with VV <150 ml (Table II). It is also interesting that the 
question relating to the force of the urinary stream in the VPSS (Q3) 
but not in the IPSS (Q5) showed a statistically significant correlation 
with Qmax and Qave in the group with VV >150 ml (Table II). This 
correlation was of the same order of magnitude as the correlations 
of total IPSS and VPSS v. Qmax and Qave (around 0.3), suggesting 
that Q3 of the VPSS on its own may prove as useful as the complete 
IPSS or VPSS. However, further study is indicated to confirm these 
findings. 
Conclusions
The VPSS correlates significantly with the IPSS, regardless of VV, 
and the VPSS is equivalent to the IPSS in terms of correlation with 
Qmax and Qave in men with LUTS. This indicates that the VPSS can 
be used instead of the IPSS for the assessment of symptom severity in 
men with LUTS who are illiterate or have limited education.  
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      An eerie silence;
      Birds, crickets, bees, trees are still -
      Rain is imminent.
Haiku: Peter Folb
